Microsoft powerpoint - neu fire-posterasco2002.ppt [schreibgesch.tzt]

Irinotecan plus Oxaliplatin versus Irinotecan plus 5-FU/Folinic Acid as First-Line Treatment
in Metastatic Colorectal Cancer: Interim Toxicity Analysis of a Randomized Phase III Trial.
A. Schalhorn1, M. Stauch2, D. Quietzsch3, P. A. Maubach4, L. Fischer von Weikersthal5, G. Schlimok6, U. Bruntsch7, H. Lambertz8, M. Grundeis9, M. Schulze10, J. Stamp, W. Hiddemann1, and V. Heinemann1
1Medical Dept. III, University of Munich, 2Oncologic Practice, Kronach, 3Dept. of Oncology, Clinic Chemnitz, 4Oncologic Practice, Ingolstadt, 5Medical Dept. II, Clinic St. Marien Amberg, 6Medical Dept. II, Clinic Augsburg,
7Medical Dept.V, Clinic Nuernberg Nord, 8Dept. of Oncology, Clinic Garmisch, 9Oncologic Practice, Chemnitz, 10Dept. of Oncology, Clinic Zittau
Abstract: 594
Purpose: This phase III multicenter trial was designed to compare the • Primary endpoint:
Inclusion criteria
efficacy and toxicity of a first-line treatment with 5-FU/FA plus irinotecan Medizinische Universitätsklinik Würzburg (arm A) to the combination of irinotecan plus oxaliplatin (arm B) in • Secondary endpoints:
z histologically proven adenocarcinoma of colon or rectum metastatic CRC. Patients and Methods: Between July 2000 and Privatklinik Dr. R. Schindlbeck Herrsching Fischer von Weikersthal Klinikum St. Marien Amberg Campto + AIO
Campto + Oxaliplatin
November 2001, 159 pts from 36 centres were enrolled. Patients (pts) z bidimensionally measurable lesions (CT/MRT >20mm, chest X-ray were randomised to receive either irinotecan 80mg/m2 plus FA 500mg/m2 plus 5-FU 2000 mg/m2 (24h) given weekly for 6 times (arm A) or oxaliplatin 85mg/m2 (d1, 15, 29) followed by irinotecan 80mg/m2 weekly z no previous chemotherapy for metastatic disease times 6 (arm B). Cycles were repeated on day 50 in both arms. A cross- over design allowed to switch over progressing pts to the respective Campto + Oxaliplatin Campto + AIO
z clinical evaluation < 3 weeks before randomisation comparator regimen. Results: To date, toxicity data are evaluable in 42 pts receiving arm A (median age: 65 yrs; male/female: 29/13) in 69 cycles Stratification:
Exclusion criteria
and in 46 pts treated in arm B (median age: 63 yrs; male/female 30/16) in z Performance Status: Karnofsky Index: 100% vs 70-90%
96 cycles. Dose reductions (<80% of planned dose) were observed for 5- FU in 29% (arm A), irinotecan in 14%/16% (arm A/B), and for oxaliplatin in O LDH: < 240 U/L versus >240 U/L
34% of cycles (arm B). Conclusion: Toxicity was acceptable in both O Adjuvant pretreatment:
treatment arms and no signficant difference was observed in the planned O clinically symptomatic peritoneal carcinosis (ascites) CPT 80 mg/m2 0.5h, day 1, 8, 15, 22, 29, 36, sample size:
Irinotecan plus FU/FA
Irinotecan plus Oxaliplatin
Safety Parameter
O chronic inflammatory GI disease / ileus based on TTP improvement from 6.7 months to 8.5 months (25%)
O clinical y symptomatic brain metastasis Hematological Toxicity (per cycle analysis) Parameter
Total (%) Arm A (%) Arm B (%)
NCI-CTC Grade 3-4 Toxicity
median(range) median(range)
Adjuvant Pretreatment
Total (%)
Age (years)
62 (28-76)
63 (32-83)
62 (28-76)
Gender (m/f)
LDH <240 U/l
Dose reduction
Colon cancer
LDH >240 U/l
CPT-11 + FU/FA
CPT-11 + Oxaliplatin
Rectal cancer
Performance status 100%
Cycles delayed
Performance status
Neutropenic Fever
Non-Hematological Toxicity (per cycle analysis) Neutropenic Fever
• Toxicity was acceptable in both treatment arms.
NCI-CTC Grade 3-4 Toxicity
• Hematotoxicity (grade 3-4) was low and generally (CPT/FuFA)
Diarrhea early
Arm A (%) Arm B (%)
Diarrhea delayed
23.5 30.9 7.4
• Non-hematological toxicity (grade 3-4) occurred in Total (%)
Arm A (%) Arm B (%)
Complete remission
<6% of cycles (apart from delayed diarrhea).
5-FU / FA Bolus
Cholinergic Synd.
Progression of disease
Patients recuited
5-FU / FA High-dose (AIO)
• Delayed diarrhea (grade 3-4) was significantly Patients evaluable for
more frequent (19.4% vs 6.7%, p=0.0005) in Mucositis
patients receiving the CPT-11/oxaliplatin Toxicity
Cycles evaluable for toxicity
Immune therapy
• Doses were reduced in 25% of cycles and were


P L A Q U E X ® IV Information for Physicians WHAT IS PLAQUEX® ? Plaquex® is an essential phospholipid formula containing polyenylphosphatidylcholine given as a series of infusions to clear clogged arteries. Plaquex® GENERAL INFORMATION General Information 1. The most important effect of Plaquex® is its remarkable ability to reduce deposits of Plaque (soft

Microsoft word - bcg instructions.doc

BCG Oncology, PC 16620 N 40th St., Suite E Patient Instructions for BCG Immunotherapy BCG stands for Bacillus Calmette-Guerin, a living but weakened tuberculosis vaccine developed by Drs. Calmette and Guerin in France in 1921. It has been and continues to be used as a vaccine to protect against TB and has been given to over one billion infants. Based on studies directed by Dr. Lamm, BC

Copyright ©2018 Sedative Dosing Pdf